Search

Your search keyword '"Crow, Andrew R."' showing total 50 results
Start Over Author "Crow, Andrew R."
50 results on '"Crow, Andrew R."'

17. Treating murine inflammatory diseases with an anti-erythrocyte antibody

Author

Crow, Andrew R., primary, Kapur, Rick, additional, Koernig, Sandra, additional, Campbell, Ian K., additional, Jen, Chao-Ching, additional, Mott, Patrick J., additional, Marjoram, Danielle, additional, Khan, Ramsha, additional, Kim, Michael, additional, Brasseit, Jennifer, additional, Cruz-Leal, Yoelys, additional, Amash, Alaa, additional, Kahlon, Simrat, additional, Yougbare, Issaka, additional, Ni, Heyu, additional, Zuercher, Adrian W., additional, Käsermann, Fabian, additional, Semple, John W., additional, and Lazarus, Alan H., additional

Published
2019
Full Text
View/download PDF

35. Defective thymic T cell activation by concanavalin A and anti-CD3 in autoimmune nonobese diabetic mice

Author

Zipris, Danny, Lazarus, Allan H., Crow, Andrew R., Hadžija, Mirko, and Delovitch, Terry L.

Subjects
Diabetes mellitus, thymic mouse cells, T-rosettes
Abstract

In nonobese diabetic (NOD) mice, T cells play a major role in mediating autoimmunity against pancreatic islet beta-cells. We and others previously reported that age-related alterations in the thymic and peripheral T cell repertoire and function occur in prediabetic NOD mice. To study the mechanism responsible for these T cell alterations, we examined whether a defect exists in the thymus of NOD mice at the level of TCR-mediated signaling after activation by Con A and anti-CD3. We found that thymocytes from NOD mice respond weakly to Con A- and anti-CD3-induced proliferation, compared with thymocytes from control BALB/c, BALB.B, (BALB.B x BALB.K)F1, C57BL/6, and nonobese non-diabetic mice. This defect correlates with the onset of insulitis, because it can be detected at 7 to 8 weeks of age, whereas younger mice displayed a normal T cell responsiveness. Thymic T cells from (NOD x BALB/c)F1 mice, which are insulitis- and diabetes-free, exhibit an intermediate stage of unresponsiveness. This T cell defect is not due to a difference in the level of CD3 and IL-2R expression by NOD and BALB/c thymocytes, and both NOD CD4+ CD8- and CD4- CD8+ mature thymic T cells respond poorly to Con A. BALB/c but not NOD thymic T cells respond to Con A in the presence of either BALB/c or NOD thymic APC, suggesting that the thymic T cell defect in NOD mice is intrinsic to NOD thymic T cells and is not due to an inability of NOD APC to provide a costimulatory signal. The defect can be partially reversed by the addition of rIL-2 to NOD thymocytes. To determine whether a defect in signal transduction mediates this NOD thymic T cell unresponsiveness, we tested whether these cells elevate their intracellular free Ca2+ ion concentration in response to Con A. An equivalent Con A-induced increase in Ca2+ ion concentration in both NOD and BALB/c thymocytes was observed, suggesting a normal coupling between the CD3 complex and phospholipase C in NOD thymocytes. In contrast to their low proliferative response to Con A or anti-CD3, NOD thymocytes respond normally (i.e., as do BALB/c thymocytes) to the combinations of PMA plus the Ca2+ ionophore ionomycin and PMA plus Con A but weakly to Con A plus ionomycin. Our data suggest that the age-related NOD thymocyte unresponsiveness to Con A and anti-CD3 results from a defect in the signaling pathway of T cell activation that occurs upstream of protein kinase C activation.

Published
1991

48. A role for IL-1 receptor antagonist or other cytokines in the acute therapeutic effects of IVIg?

Author

Crow, Andrew R., Song, Seng, Semple, John W., Freedman, John, and Lazarus, Alan H.

Abstract

The exact mechanism of action of IVIg in the amelioration of immune thrombocytopenic purpura (ITP) is still unclear. Studies have suggested that IVIg may function through the regulation of cytokines, including interleukin-1 receptor antagonist (IL-1Ra), an inhibitor of phagocytosis. Using a mouse model relevant to ITP, we confirm an increase in mouse serum levels of IL-1Ra after exposure to IVIg, yet a recombinant IL-1Ra did not ameliorate thrombocytopenia. IVIg has also been shown to affect the expression of other regulatory cytokines. We have also recently established that IVIg specifically targets activating FcγRs on CD11c+ dendritic cells (DCs) as its primary mechanism of action in the amelioration of murine ITP. Herein, we show that IVIg functions therapeutically in mice lacking specific cytokines or their receptors that can potentially affect DC/macrophage function (IL-1 receptor, IL-4, IL-10, IL-12β, TNF-α, IFN-γ receptor, MIP-1α). This suggests that while IVIg may mediate the release of a variety of cytokines, the cytokines tested do not directly participate in the mechanism of IVIg action.

Published
2007
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results